• Newly formed Operating Partners group and Clinical and Scientific Advisory Board to provide critical insights to support portfolio companies’ success and guide investment strategies
  • Additional facility expected to catalyze the growth of innovative life science companies in Southern California

SEATTLE and NEW YORK – May 15, 2018 — Accelerator Life Science Partners (Accelerator), a leading life science investment and management firm, today announced that it has expanded its operations into San Diego and the Greater Los Angeles area with the opening of a new office at The Alexandria at Torrey Pines in San Diego. The firm also announced the formation of its Operating Partners group and Clinical and Scientific Advisory Board (CSAB). These strategic growth initiatives will better enable Accelerator to fulfill its dual missions of providing unique and compelling opportunities to its investors and partnering with cutting-edge life science companies to help achieve their near-term milestones and long-term visions.

“Accelerator is committed to supporting innovation wherever it takes place and without geographic limitation,” said David M. Schubert, chief operating partner at Accelerator. “Opening an office in San Diego, our third market, positions us to meet the needs of leading innovators throughout the vibrant San Diego and emerging Greater Los Angeles life science ecosystems. We have also brought together an experienced group of Operating Partners to support our ongoing efforts to identify new investment areas and specific company-building opportunities.”

Accelerator’s Operating Partners will assist with the evaluation of new business opportunities, support current (and future) Accelerator portfolio companies and serve in a variety of operating and board roles. The Operating Partners include:

  • Andrew Howard, Ph.D. (New York City, NY)
  • Wendy S. Johnson (San Diego, CA)
  • David L. Pompliano, Ph.D. (New York City, NY)
  • Francisco D. Salva (Philadelphia, PA)
  • John T. Santini, Jr., Ph.D. (Minneapolis, MN)
  • David M. Schubert  (New York City, NY)
  • Christopher T oombs, Ph.D. (Seattle, WA)
  • Court R. Turner, J.D. (San Diego, CA)

“Having state-of-the-art laboratories and world-class scientific leadership will help set our portfolio companies on a path to long-term success,” said Kendall Mohler, Ph.D., chief development officer at Accelerator. “We are excited to welcome our CSAB members to the Accelerator team. Advancing a groundbreaking scientific idea into and through clinical development takes not only robust data; it also requires critical insights into preclinical research, clinical trial design and strategy and keen understanding of the product approval pathway. Our CSAB members have demonstrated expertise in these areas, and we believe they will be an important asset as we partner with today’s most cutting-edge entrepreneurs.”

Accelerator’s CSAB Members:

  • Lee E. Babiss, Ph.D.
  • John Latham, Ph.D.
  • George L. McLendon, Ph.D.
  • Kendall M. Mohler, Ph.D.
  • Gerald T. Nepom, M.D., Ph.D.
  • Homer L. Pearce, Ph.D.
  • Anil K. Singhal, Ph.D.
  • James Tobin, Ph.D.

Additional information about the members of Accelerator’s Operating Partners and CSAB is available at: www.acceleratorlsp.com/our-team/.

About Accelerator Life Science Partners
Accelerator Life Science Partners catalyzes the development and commercialization of breakthrough biotechnology innovations. Accelerator is a trusted partner that provides the complete business, scientific and financial toolkit necessary for successfully establishing and operating an early-stage biotechnology company. Accelerator nurtures its companies across all stages and in all facets of development, setting them on a path that offers the greatest chance for long-term success. Among these key resources are committed investment capital, experienced start-up management, world-class scientific expertise and state-of-the-art laboratories and shared facilities.

The company is uniquely positioned to provide this unprecedented collection of capabilities and resources through its partnership with top-tier investors, seasoned executive managers and world-class research institutions. The value of these collective resources has been validated over more than a decade of successful investing in life science companies that are helping to shape the rapidly evolving future of medicine and healthcare. For more information, please visit www.acceleratorlsp.com


Media Contacts:

Rathbun Communications
Julie Rathbun

Accelerator Life Science Partners
Jessica Burback
T: 206-234-6481